Share this Post
Posted on: June 14, 2019
Bio X Cell In Print
Prophylactic treatment with antagonistic anti-TNFα antibodies may improve outcomes of anti-PD-1 and anti-CTLA-4 combination cancer immunotherapy
The combination of anti-PD-1 and anti-CTLA-4 antibody-mediated immunotherapy is remarkably effective against melanoma, renal cell carcinoma, and non-small-cell lung cancer. However, this comes at the cost of frequent, serious immune-related adverse events. Colitis is among the most frequent and problematic of the immune-mediated adverse events that are associated with dual checkpoint inhibition.
We Broke Ground
On May 28th Bio X Cell owner, Dr. Klaus Lubbe, gave a wonderful speech thanking Bio X Cell employees and all of the engineers, architects, city planners and contractors who have helped to make this vision a reality. Click here to view pictures and updates on Bio X Cell’s new space!
BioResearch Product Faire™
On Friday, June 28th from 10am-2:30pm Bio X Cell will be exhibiting at The University of Pittsburgh for the BioResearch Product Faire™. This is an excellent opportunity for Graduate Students, Post Doctoral Candidates, Professors, Research Scientists, Grant Holders, Principal Investigators, Lab Managers or University Purchasing Agents to learn about Bio X Cell’s unmatched antibodies! This event is fully catered and FREE for University of Pittsburgh life science research professionals to attend.
To have this blog update emailed directly to you, signup for our monthly newsletters. You will also receive one-of-a-kind monthly product promotional discount codes for our Featured Product of the month! Scroll down and enter your email into the box provided.